Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals reported first-quarter 2026 financial results, with $0.2 million in product revenue from the launch of CARDAMYST™ (etripamil) nasal spray for PSVT. The company secured national formulary coverage from Express Scripts, making CARDAMYST more accessible and affordable for commercially insured patients. Approximately 400 unique prescribers have started patients on the drug, and over 25% of commercially insured lives in the U.S. now have coverage.
Key figures
- Revenue
- 238000
- Net loss
- 26066000
- Commercial expense
- 15812000
- Short term investments
- 112899000
- Cash and cash equivalents
- 71317000
- Research and development expense
- 3251000
- General and administrative expense
- 4824000
- Weighted average shares outstanding
- 130286033
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.